Clinical Trials Browser

NCT04332653 2026-03-09

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

BreastGastrointestinalGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Thoracic Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07052305 2026-02-12

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Phase 1 Recruiting

24 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

NCT05286060 2026-02-09

GENUINE

Phase 2 Active not recruiting

56 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05465954 2026-01-12

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Phase 2 Recruiting

54 enrolled

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT03687957 2025-11-25

rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide

Phase 1/2 Active not recruiting

42 enrolled 19 charts

CNS

Glioma

NCT05075603 2025-10-23

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

Phase 1 Completed

17 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03901573 2025-10-22

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

Phase 1/2 Terminated

31 enrolled 12 charts

Dermatologic

Melanoma, Carcinoma, Merkel Cell

NCT07200089 2025-09-30

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

Phase 1 Not yet recruiting

40 enrolled

Plasma cell

Multiple Myeloma

NCT04588038 2025-02-14

NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery

Phase 1 Terminated

4 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04594811 2024-08-16

NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma

Phase 1 Terminated

10 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04893018 2024-06-27

NT-I7 for Kaposi Sarcoma in Patients With or Without HIV

Phase 1 Terminated

8 enrolled 14 charts

Sarcoma

AIDS-related Kaposi sarcoma, Sarcoma, Kaposi, HIV Infections

NCT06344715 2024-04-03

Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.

Phase 1 Recruiting

78 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT03752723 2024-03-05

KEYNOTE-899

Phase 1/2 Completed

84 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04984811 2024-03-05

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

Phase 2 Active not recruiting

83 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04054752 2023-11-02

Vaccine Response With NT-I7

Phase 1 Withdrawn

BreastGastrointestinalGenitourinary

Urinary Bladder Neoplasms, Breast Neoplasms, Colorectal Neoplasms

NCT02659800 2023-10-06

Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas

Phase 1 Terminated

12 enrolled

CNS

Glioma, Lymphopenia

NCT05191784 2023-06-12

GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients

Phase 2 Unknown

20 enrolled

CNS

Glioblastoma

NCT04065087 2022-03-17

Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma

Phase 1/2 Withdrawn

CNS

Newly Diagnosed Glioblastoma

NCT04289155 2022-03-17

Individual Patient Compassionate Use of GX-I7

No longer available

CNSDermatologic

Glioblastoma, Glioma, Melanoma

NCT03733587 2020-05-14

GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors

Phase 1 Completed

24 enrolled

Other solid neoplasm

Solid Tumor

NCT03478995 2020-05-11

Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

35 enrolled

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

NCT00923351 2018-06-15

Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma

Phase 1/2 Completed

44 enrolled 13 charts

CNSSarcoma

Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal, Neuroectodermal Tumors, Primitive, Peripheral

NCT03206138 2017-07-02

Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.

Phase NA Unknown

50 enrolled

Gynecologic

Uterine Cervical Dysplasia